Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.
Alongside full PIK3CA wild-type data, Celcuity sets the bar for gedatolisib's PIK3CA-mutant readout.
The company reveals the first overall survival data in adjuvant ER-positive breast cancer.
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
